BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21631893)

  • 1. Metformin as an antitumor agent in cancer prevention and treatment.
    Li D
    J Diabetes; 2011 Dec; 3(4):320-7. PubMed ID: 21631893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
    Hosono K; Endo H; Takahashi H; Sugiyama M; Uchiyama T; Suzuki K; Nozaki Y; Yoneda K; Fujita K; Yoneda M; Inamori M; Tomatsu A; Chihara T; Shimpo K; Nakagama H; Nakajima A
    Mol Carcinog; 2010 Jul; 49(7):662-71. PubMed ID: 20564343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
    Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin: taking away the candy for cancer?
    Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
    Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.
    Pierotti MA; Berrino F; Gariboldi M; Melani C; Mogavero A; Negri T; Pasanisi P; Pilotti S
    Oncogene; 2013 Mar; 32(12):1475-87. PubMed ID: 22665053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
    Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
    Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
    Ben Sahra I; Laurent K; Loubat A; Giorgetti-Peraldi S; Colosetti P; Auberger P; Tanti JF; Le Marchand-Brustel Y; Bost F
    Oncogene; 2008 Jun; 27(25):3576-86. PubMed ID: 18212742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and cancer therapy.
    Bost F; Sahra IB; Le Marchand-Brustel Y; Tanti JF
    Curr Opin Oncol; 2012 Jan; 24(1):103-8. PubMed ID: 22123231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.
    Algire C; Amrein L; Bazile M; David S; Zakikhani M; Pollak M
    Oncogene; 2011 Mar; 30(10):1174-82. PubMed ID: 21102522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
    Zakikhani M; Dowling R; Fantus IG; Sonenberg N; Pollak M
    Cancer Res; 2006 Nov; 66(21):10269-73. PubMed ID: 17062558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it time to test biguanide metformin in the treatment of melanoma?
    Cerezo M; Tomic T; Ballotti R; Rocchi S
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):8-20. PubMed ID: 24862830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
    Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
    Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
    Gallagher EJ; LeRoith D
    Ann N Y Acad Sci; 2011 Dec; 1243():54-68. PubMed ID: 22211893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New perspective for an old antidiabetic drug: metformin as anticancer agent.
    Leone A; Di Gennaro E; Bruzzese F; Avallone A; Budillon A
    Cancer Treat Res; 2014; 159():355-76. PubMed ID: 24114491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin in cancer: translational challenges.
    Dowling RJ; Niraula S; Stambolic V; Goodwin PJ
    J Mol Endocrinol; 2012 Jun; 48(3):R31-43. PubMed ID: 22355097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
    Wysocki PJ; Wierusz-Wysocka B
    Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets of metformin antitumor action.
    Sośnicki S; Kapral M; Węglarz L
    Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin, cancer and glucose metabolism.
    Salani B; Del Rio A; Marini C; Sambuceti G; Cordera R; Maggi D
    Endocr Relat Cancer; 2014; 21(6):R461-71. PubMed ID: 25273809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer research. Cancer prevention with a diabetes pill?
    Taubes G
    Science; 2012 Jan; 335(6064):29. PubMed ID: 22223788
    [No Abstract]   [Full Text] [Related]  

  • 20. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
    Zakikhani M; Blouin MJ; Piura E; Pollak MN
    Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.